Zealand Pharma A/S

Copenhagen Stock Exchange:ZEAL.CO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Denmark

Market Cap

USD 4.10 B

Share Price

USD 57.74

Avg Daily Volume

493,779

Change (1 day)

-2.93%

Change (1 year)

-37.71%

Change (YTD)

-41.98%

Zealand Pharma A/S Interest Coverage Ratio for the year ending December 31, 2024: -25.49

Zealand Pharma A/S Interest Coverage Ratio is -25.49 for the year ending December 31, 2024, a 9.17% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Zealand Pharma A/S Interest Coverage Ratio for the year ending December 31, 2023 was -23.35, a 43.97% change year over year.
Zealand Pharma A/S Interest Coverage Ratio for the year ending December 31, 2022 was -16.22, a -91.21% change year over year.
Zealand Pharma A/S Interest Coverage Ratio for the year ending December 31, 2021 was -184.50, a -14.71% change year over year.
Zealand Pharma A/S Interest Coverage Ratio for the year ending December 31, 2020 was -216.32, a 20.93% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Interest Coverage Ratio	Return on Capital Employed (ROCE)	Return on Equity (ROE)	Return on Assets (ROA)

Copenhagen Stock Exchange: ZEAL.CO

Zealand Pharma A/S

CEO	Mr. Adam Sinding Steensberg M.D.
IPO Date	Nov. 23, 2010
Location	Denmark
Headquarters	Sydmarken 11
Employees	385
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.